Vivos Therapeutics price to sales ratio VVOS

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: 0.1×
5-year median: 0.8×
Against its 5-year history: 0th; percentile: 0 is its lowest day, 100 its highest
5-year range: 0.1× to 4.8×
Peer median: 1.4×

Vivos Therapeutics' price to sales ratio is 0.1× as of Oct 23, 2026.

That is below its 5-year median of 0.8×, lower than on 100% of days in the last 5 years.

Over that time it ranged from 0.1× in Oct 2026 to 4.8× in Mar 2022.

The median for 10 healthcare stocks of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.1×	0.1×	1.3×
2025	1.1×	0.8×	2.7×
2024	1.5×	0.4×	1.7×
2023	1.0×	0.2×	2.4×
2022	0.6×	0.5×	4.8×
2021	3.3×	3.3×	4.0×

Against its peers

Companies in Healthcare nearest Vivos Therapeutics' size, closest first, today.

Company	Price to sales ratio
VVOSVivos Therapeutics	0.1×
OXBROXBRIDGE RE HOLDINGS	2.8×
EDUCEducational Development	0.4×
GTIMGood Times Restaurants	0.1×
MDRRMedalist Diversified	1.6×
BCGBinah Capital	0.1×
VIPVulcan Infrastructure & Power	0.4×
MXCMexco Energy	3.0×
CKXCKX Lands	31.0×
MSGMMotorsport Games	1.5×
ATCHAtlasClear	1.2×
Peer median	1.4×

Where Vivos Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Vivos Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.